VEGF-B Is an Autocrine Gliotrophic Factor for Müller Cells under Pathologic Conditions.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
01 09 2020
Historique:
entrez: 18 9 2020
pubmed: 19 9 2020
medline: 1 4 2021
Statut: ppublish

Résumé

Müller glia are important in retinal health and disease and are a major source of retinal VEGF-A. Of the different VEGF family members, the role of VEGF-A in retinal health and disease has been studied extensively. The potential contribution of other VEGF family members to retinal pathophysiology, however, remains poorly defined. This study aimed to understand the role of VEGF-B in Müller cell pathophysiology. The expression of different VEGFs and their receptors in human MIO-M1 and mouse QMMuC-1 Müller cell lines and primary murine Müller cells was examined by RT-PCR, ELISA, and Western blot. The effect of recombinant VEGF-B or VEGF-B neutralization on Müller cell viability and survival under normal, hypoxic, and oxidative (4-hydroxynonenal [4-HNE]) conditions was evaluated by Alamar Blue, Yo-Pro uptake, and immunocytochemistry. The expression of glial fibrillary acidic protein, aquaporin-4, inward rectifying K+ channel subtype 4.1, glutamine synthetase, and transient receptor potential vanilloid 4 under different treatment conditions was examined by RT-PCR, immunocytochemistry, and Western blot. Transient receptor potential vanilloid 4 channel activity was assessed using a Fura-2-based calcium assay. VEGF-B was expressed in Müller cells at the highest levels compared with other members of the VEGF family. VEGF-B neutralization did not affect Müller cell viability or functionality under normal conditions, but enhanced hypoxia- or 4-HNE-induced Müller cell death and decreased inward rectifying K+ channel subtype 4.1 and aquaporin-4 expression. Recombinant VEGF-B restored Müller cell glutamine synthetase expression under hypoxic conditions and protected Müller cells from 4-HNE-induced damage by normalizing transient receptor potential vanilloid 4 channel expression and activity. Autocrine production of VEGF-B protects Müller cells under pathologic conditions.

Identifiants

pubmed: 32945843
pii: 2770817
doi: 10.1167/iovs.61.11.35
pmc: PMC7509798
doi:

Substances chimiques

Glial Fibrillary Acidic Protein 0
Vascular Endothelial Growth Factor B 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Subventions

Organisme : Medical Research Council
ID : MC_PC_15026
Pays : United Kingdom

Références

Cancer Res. 2006 Nov 15;66(22):10919-28
pubmed: 17108129
Physiol Rev. 2014 Jul;94(3):779-94
pubmed: 24987005
Sci Rep. 2016 May 18;6:26059
pubmed: 27189805
Eye (Lond). 2019 Apr;33(4):600-609
pubmed: 30401898
Parkinsons Dis. 2017;2017:4263795
pubmed: 28473940
J Neurochem. 2005 Aug;94(3):691-702
pubmed: 16033419
Mol Cell Biol. 2008 Aug;28(15):4843-50
pubmed: 18519586
Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10351-10356
pubmed: 30249667
Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2576-81
pubmed: 8637916
Cardiovasc Diabetol. 2016 Jan 29;15:18
pubmed: 26822858
Ophthalmologica. 2012;227(1):1-19
pubmed: 21921569
J Biol Chem. 2014 Feb 7;289(6):3383-93
pubmed: 24356956
Vis Neurosci. 2010 Nov;27(5-6):139-47
pubmed: 20932358
Diabetes. 2006 Mar;55(3):633-9
pubmed: 16505225
J Neurosci. 2018 Oct 10;38(41):8745-8758
pubmed: 30143574
Respir Res. 2014 Mar 19;15:32
pubmed: 24641672
Mol Vis. 2007 Mar 01;13:309-17
pubmed: 17356517
Front Cell Neurosci. 2017 Feb 27;11:20
pubmed: 28289375
J Biol Chem. 2001 Jun 1;276(22):19166-71
pubmed: 11279005
Elife. 2016 Mar 15;5:
pubmed: 26978795
J Exp Med. 2003 Sep 15;198(6):863-8
pubmed: 12963694
Invest Ophthalmol Vis Sci. 2011 Jun 01;52(6):3784-91
pubmed: 21310918
J Neurosci. 2014 Nov 19;34(47):15689-700
pubmed: 25411497
Organogenesis. 2010 Apr-Jun;6(2):107-14
pubmed: 20885857
Med Sci (Basel). 2017 Aug 09;5(3):
pubmed: 29099033
Pharmacol Res. 2019 May;143:33-39
pubmed: 30851357
Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17272-7
pubmed: 25404333
Drug Discov Today. 2019 Aug;24(8):1483-1498
pubmed: 30731239
PLoS One. 2015 Mar 20;10(3):e0120415
pubmed: 25793273
Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E5944-53
pubmed: 26483474
Cell Death Dis. 2019 May 7;10(5):364
pubmed: 31064977
Vision Res. 2017 Oct;139:108-114
pubmed: 28601428
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6152-7
pubmed: 19369214
Prog Retin Eye Res. 2006 Jul;25(4):397-424
pubmed: 16839797
Diabetes. 2010 Sep;59(9):2297-305
pubmed: 20530741
J Cereb Blood Flow Metab. 2013 Nov;33(11):1685-95
pubmed: 23963372
Vision Res. 2017 Oct;139:93-100
pubmed: 28866025
J Neurosci. 2015 Sep 30;35(39):13525-37
pubmed: 26424896
Sci Rep. 2016 Aug 11;6:30583
pubmed: 27510430
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3885-90
pubmed: 27006502
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6157-62
pubmed: 23530219
Br J Ophthalmol. 2003 Sep;87(9):1159-66
pubmed: 12928288
Neural Regen Res. 2018 Oct;13(10):1741-1742
pubmed: 30136688
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):864-9
pubmed: 11867609
Front Pharmacol. 2018 Nov 06;9:1267
pubmed: 30459621
Invest Ophthalmol Vis Sci. 2015 Dec;56(13):8031-44
pubmed: 26720454
Brain. 2002 Nov;125(Pt 11):2549-57
pubmed: 12390979
PLoS One. 2010 Jul 19;5(7):e11654
pubmed: 20657843
Sci Rep. 2015 Dec 16;5:18316
pubmed: 26671074
J Cell Biochem. 2017 Aug;118(8):2302-2313
pubmed: 28098409
Trends Mol Med. 2012 Feb;18(2):119-27
pubmed: 22178229
J Clin Invest. 2008 Mar;118(3):913-23
pubmed: 18259607
Curr Eye Res. 2001 May;22(5):341-7
pubmed: 11600934
Nat Genet. 2001 Jun;28(2):131-8
pubmed: 11381259
Invest Ophthalmol Vis Sci. 2011 Aug 11;52(9):6340-7
pubmed: 21724913
J Thorac Oncol. 2006 Oct;1(8):768-70
pubmed: 17409958
Invest Ophthalmol Vis Sci. 2018 Mar 1;59(3):1666-1674
pubmed: 29625493
J Mol Cell Cardiol. 2000 Nov;32(11):1955-67
pubmed: 11040101

Auteurs

María Llorián-Salvador (M)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Peter Barabas (P)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Eimear M Byrne (EM)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Judith Lechner (J)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Josy Augustine (J)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Timothy M Curtis (TM)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Mei Chen (M)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Heping Xu (H)

Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, BT9 7BL. Belfast, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH